CP 42,096.

CP 42,096 belongs to the CP series of synthetic cannabinoids. The tertiary Wikipedia pointer attributes it to Pfizer in the 1980s. A study by Koe et al., published in 1985, describes it as a cannabimimetic that increases, in mice and in vivo, the binding of [3H]flunitrazepam to the brain, and that shows analgesic activity. No affinity constant for CB1 or CB2 receptors is published in the consulted sources, and no human data was found there. The compound is not named in the French narcotics list; its structure matches the generic clause for benzo[c]chromenes at three of its four substituted positions, but the position 9 hydroxyl is not clearly covered by the definition, so its status remains uncertain.

Source

Wholly synthetic molecule. No consulted source describes it in hemp or in any other living organism: it is known only as a laboratory compound, used in pharmacological research on cannabinoid receptors.

No biosynthetic route: CP 42,096 is produced by no living organism described in the consulted sources. It belongs to synthetic chemistry alone, in the class of hydrogenated benzo[c]chromenes bearing an alkyl ether at position 3.

European Union

No harmonised control measure at European Union level is documented for CP 42,096 in the consulted sources: control therefore rests with the member states. At international level, it is not listed in the INCB Green List 2026, which does list tetrahydrocannabinols and HHC under different structures (entries PT 002 and PH 003).

France

CP 42,096 is not named in the consolidated list of substances classified as narcotics, updated on 16 February 2026. It could fall under the generic clause for benzo[c]chromene derivatives, in annex IV of that list (decisions of 22 May and 3 June 2024): its ring A is fully hydrogenated, and its positions 1 (hydroxyl), 3 (alkoxy chain) and 6 (two alkyl groups) match the permitted substituents. Its position 9, however, bears a direct hydroxyl group, which the definition does not list among the permitted substituents (ketone, alkyl, hydroxyalkyl or alkoxy), and the text does not state with certainty whether it falls under 'hydroxyalkyl'. The status is therefore uncertain. It is neither CBN, nor THCV, nor THCA, the cannabinoids excluded by the clause.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

1. 1Koe et coll., amélioration de la liaison cérébrale du [3H]flunitrazépam et activité analgésique des cannabimimétiques de synthèse, European Journal of Pharmacology 1985 (new tab)PMID 2986995
2. 2ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, clause des benzo[c]chromènes, décisions des 22 mai et 3 juin 2024) (new tab)
3. 3ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (new tab)
4. 4ANSM, décision du 3 juin 2024 portant modification de la liste des substances classées comme stupéfiants (new tab)
5. 5INCB, Liste verte 2026 au titre de la Convention de 1971 (entrées PT 002 et PH 003) (new tab)
6. 6PubChem, CID 10070164, CP 42,096 (identifiants et propriétés) (new tab)
7. 7Wikipédia EN, article CP 42,096 (repère tertiaire) (new tab)

SMILES

CC(CCCC1=CC=CC=C1)OC2=CC(=C3[C@@H]4C[C@@H](CC[C@H]4C(OC3=C2)(C)C)O)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.